FP7HORIZONH2020
Eurofins Genomics Europe Pharma and Diagnostics Products & Services Sanger Pcr GmbH
- Country
- DEGermany
- Defence projects
- 0
- Projects, all programmes
- 14
- As coordinator
- 0
- EU contribution (CORDIS)
- EUR 9,627,459
- Active
- 2008 to 2024
Projects
14 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| TextaDNAHigh-throughput oligonucleotide synthesis and NGS for Digital TEXT Storage And retrieval in DNA encapsulated nanofibers | HORIZON | 2024 | Participant | EUR 1,348,750 |
| BarleyMicroBreedStrategies for breeding climate change resilient barley, genetically equipped to optimized root-microbiome interactions | HORIZON | 2022 | Participant | EUR 1,097,250 |
| FORECEEFemale cancer prediction using cervical omics to individualise screening and prevention | H2020 | 2015 | Participant | EUR 558,970 |
| EUROFANCOLENPhase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action | FP7 | 2013 | Participant | EUR 654,192 |
| SYBILSystems biology for the functional validation of genetic determinants of skeletal diseases | FP7 | 2013 | Participant | EUR 849,780 |
| HUMANHealth and the Understanding of Metabolism, Aging and Nutrition | FP7 | 2013 | Participant | EUR 749,749 |
| EPI-FEM-CAREEPIGENETICS FOR FEMALE PERSONALIZED CANCER CARE | FP7 | 2012 | Participant | EUR 2,136,106 |
| BEANBEAN – Bridging the European and Anatolian Neolithic: Demography, Migration, and Lifestyle at the Advent of Civilization | FP7 | 2012 | Participant | Not stated |
| NET4CGDGene Therapy for X-linked Chronic Granulomatous Disease (CGD) | FP7 | 2012 | Participant | EUR 240,096 |
| SYSCLADSystems prediction of Chronic Lung Allograft Dysfunction | FP7 | 2012 | Participant | EUR 416,616 |
| CELL-PIDAdvanced Cell-based Therapies for the treatment of Primary ImmunoDeficiency | FP7 | 2010 | Participant | EUR 289,400 |
| EURO-GENE-SCANEuropean Genetic Disease Diagnostics | FP7 | 2009 | Participant | EUR 749,000 |
| PERSISTPersisting Transgenesis | FP7 | 2009 | Participant | EUR 497,550 |
| TB-VIRMycobacterium tuberculosis W-Beijing genetic diversity and differential virulence and host immune responses | FP7 | 2008 | Participant | EUR 40,000 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.